Pancreatic Cancer Research

ResearcherOsaka International Cancer InstituteActive in the last 2 years

Masahiko Kubo

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5102363612. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: 3 papers · 2025: 5 papers · 2026: 1 paper

Papers 11

  1. Preoperative Gemcitabine/Nab-Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer: A Comparative Analysis With Preoperative… Co-author DOI 10.1002/ags3.70191↗
  2. Response to letter to the editor: "A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from radical surgery in resectable or b… Co-author DOI 10.1016/j.surg.2024.109053↗
  3. Reply to letter to editor by yinfang Wu, MM about our manuscript, "A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from ra… Co-author DOI 10.1016/j.surg.2024.109132↗
  4. Reply to letter to editor by Duo Yun, MD regarding our article, "A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from radi… Co-author DOI 10.1016/j.surg.2024.11.003↗
  5. miR-6855-5p Enhances Radioresistance and Promotes Migration of Pancreatic Cancer by Inducing Epithelial-Mesenchymal Transition via Suppressing FOXA1: Potential… Co-author DOI 10.1245/s10434-024-16115-w↗
  6. ASO Author Reflections: Potential of Peripheral Plasma Exosomal miRNA: miR-6855-5p Could Predict Radiosensitivity in Patients with Pancreatic Cancer, and Enhan… Co-author DOI 10.1245/s10434-024-16235-3↗
  7. Prognostic impact of aberrant right hepatic artery involvement in patients with pancreatic cancer: A multicenter retrospective cohort study. Co-author DOI 10.1002/jso.27792↗
  8. Preoperative treatment response prediction for pancreatic cancer by multiple microRNAs in plasma exosomes: Optimization using machine learning and network anal… Co-author DOI 10.1016/j.pan.2024.09.009↗
  9. A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from radical surgery in resectable and borderline resectable pancreatic ca… Co-author DOI 10.1016/j.surg.2024.06.049↗
  10. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-019-07927-2↗
  11. ASO Author Reflections: Regulation of Chemoresistance in Pancreatic Ductal Adenocarcinoma by Scavenger Receptor CD36. Co-author DOI 10.1245/s10434-019-08022-2↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hirofumi Akita · 7 shared papers, 2020–2026 · strength 1.82
  2. Hiroshi Wada · 5 shared papers, 2024–2025 · strength 1.43
  3. Yosuke Mukai · 4 shared papers, 2024–2025 · strength 1.27
  4. Tadafumi Asaoka · 5 shared papers, 2020–2025 · strength 0.89
  5. Yuichiro Doki · 5 shared papers, 2020–2025 · strength 0.89
  6. Yoshifumi Iwagami · 5 shared papers, 2020–2025 · strength 0.89
  7. Yoshito Tomimaru · 5 shared papers, 2020–2025 · strength 0.89
  8. Daisaku Yamada · 4 shared papers, 2024–2025 · strength 0.79
  9. Hiroki Ueda · 4 shared papers, 2024–2025 · strength 0.79
  10. Kazuki Sasaki · 4 shared papers, 2024–2025 · strength 0.79
  11. Hidetoshi Eguchi · 4 shared papers, 2020–2024 · strength 0.68
  12. Shinichiro Hasegawa · 3 shared papers, 2024–2026 · strength 0.62
  13. Hidenori Takahashi · 3 shared papers, 2024–2026 · strength 0.62
  14. Kunihito Gotoh · 3 shared papers, 2020–2026 · strength 0.56
  15. Hidetoshi Eguchi · 2 shared papers, 2025 · strength 0.45
  16. Reishi Toshiyama · 1 shared paper, 2024 · strength 0.17
  17. Masahiro Tanemura · 1 shared paper, 2020 · strength 0.10
  18. Yutaka Takeda · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.